Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Myriad Genetics, Inc. is a molecular diagnostics company specializing in genetic and genomic testing to inform disease risk, diagnosis, prognosis, and treatment decisions. The company operates primarily within the precision medicine, oncology, and women’s health industries, providing clinically validated tests to healthcare providers, hospitals, and health systems. Its core offerings focus on hereditary cancer risk assessment, tumor profiling, and companion diagnostics used to guide targeted therapies.
Founded in 1991, Myriad Genetics emerged from academic research in human genetics and gained prominence through the commercialization of BRCA1 and BRCA2 hereditary cancer tests in the 1990s. Over time, the company evolved from a single-test model into a diversified diagnostics platform, expanding its portfolio through internal development and acquisitions. Following changes in the competitive and intellectual property landscape in the mid-2010s, Myriad shifted strategy toward broader test menus, international expansion, and integrated clinical decision support.
Business Operations
Myriad generates revenue through the development, commercialization, and reimbursement of proprietary genetic tests performed primarily in its certified laboratories. Its major business lines include Hereditary Cancer Testing, Tumor Profiling, and Risk Assessment and Prognostic Testing, with flagship products such as myRisk, myChoice CDx, Prolaris, and EndoPredict. Testing services are reimbursed through a mix of private insurance, government payors, and institutional contracts.
Operations are conducted through Myriad Genetic Laboratories, Inc., the company’s primary operating subsidiary, which holds CLIA- and CAP-certified laboratory facilities. Myriad also maintains international operations through subsidiaries and distributors, particularly in Europe. The company collaborates with pharmaceutical partners to develop and commercialize companion diagnostics aligned with targeted oncology therapies.
Strategic Position & Investments
Myriad’s strategic direction centers on expanding its oncology diagnostics franchise, strengthening evidence-based clinical utility, and deepening integration with therapeutic decision-making. Growth initiatives have included investment in companion diagnostics, real-world clinical data generation, and expanded test indications across cancer types. Acquisitions such as Counsyl, Inc. (women’s health and carrier screening) and Sividon Diagnostics GmbH (EndoPredict breast cancer assay) broadened Myriad’s test portfolio and international reach.
The company has periodically reshaped its asset base to focus on core oncology and women’s health diagnostics. Certain prior businesses, including Assurex Health, Inc. (GeneSight pharmacogenomic testing), were previously part of Myriad’s portfolio; public disclosures indicate subsequent divestiture, though specific transaction details are not consistently reported across all public sources. Data inconclusive based on available public sources regarding the full strategic impact of this divestiture.
Geographic Footprint
Myriad Genetics is headquartered in Salt Lake City, Utah, and conducts the majority of its laboratory operations in the United States. Its tests are marketed nationwide, serving physicians, hospitals, and integrated delivery networks across all major U.S. regions. The U.S. remains the company’s largest revenue-generating market.
Internationally, Myriad maintains a commercial and operational presence in Europe, particularly in Germany, France, Italy, and the United Kingdom, supported by local subsidiaries and distribution partners. The company’s geographic strategy emphasizes selective international expansion in markets with established reimbursement frameworks for molecular diagnostics.
Leadership & Governance
Myriad Genetics was co-founded by Mark Skolnick, a geneticist whose research contributed to the discovery of BRCA genes and the company’s early scientific foundation. The leadership team emphasizes disciplined capital allocation, clinical evidence generation, and integration of diagnostics into precision oncology care pathways.
Key executives include:
- Paul J. Diaz – President and Chief Executive Officer
- R. Michael Quigley – Chief Financial Officer
- Ron Rogers – Chief Operating Officer
- James M. Kunz – Chief Medical Officer
- Nicole Lambert – Chief Commercial Officer
The company operates under a board-led governance model consistent with U.S. public company standards, with oversight of strategy, risk management, and executive compensation aligned to long-term shareholder and clinical value creation.